On May 31, 2019, Noramco, a world-leading manufacturer of controlled substances and active pharmaceutical ingredients (APIs) for the pharmaceutical industry, presented testimony and answered questions at the Food and Drug Administration’s (FDA) Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds, Part 15 Public Hearing. This presentation had significance as Noramco is the world’s largest producer of high-quality synthetic cannabinoid APIs for the pharmaceutical and healthcare industries.
Demand for cannabidiol (CBD) continues to increase and this is a trend that has caught the attention of the largest healthcare agencies in the world.
Noramco has the capability to produce high-purity CBD compounds that can form the starting point for clinical and commercial activities in every market sector (i.e., pharmaceutical, nutraceuticals, food and beverage, and personal care).
Cardiol Therapeutics Inc. (Cardiol) ( TSX: CRDL) ( OTC: CRTPF), is ahead of the curve with its strategic relationship with Noramco and is focused on the production of 100% pure premium CBD. We believe Cardiol is well positioned to be a global CBD leader.
Cardiol and Noramco: A Significant Partnership
Last year, Cardiol entered into an exclusive supply agreement with Noramco and received the exclusive rights to use Noramco’s pharmaceutical CBD in Canada and Mexico. This is an important strategic partnership for Cardiol, and we expect this to be a major value driver over the long-term.
Looking at the potential value that can be created through this relationship, we believe Cardiol is in the early innings of a major growth cycle and represents an attractive opportunity. In the second half of 2019, the company plans to launch CardiolRx, a 100% pure premium CBD product. The launching of this product should generate significant traction and has the potential to generate strong revenues once it hits the market.
Levered to the Expanding International CBD Market
We are excited about Cardiol’s supply and contract manufacturing agreement that it has with Dalton Pharma Services, whose facilities are Health Canada approved, FDA licensed, and cGMP certified. CBD products that are manufactured at the facility will meet the standards required for international markets where they are legal. The fact that these facilities meet such high standards is significant and we are bullish on the growth prospects associated with international markets.
Under the agreement, Dalton will manufacture all the materials that Cardiol needs for clinical trials, as well as their 100% pure CBD products that are intended for sale in legal markets, including Canada under the Cannabis Act. Over the next year, we expect this relationship to support the company’s overall growth prospects and find this to be an important aspect of the story.
A Company with Significant Potential Catalysts for Growth
Cardiol Therapeutics has been flying under the radar. It represents a multi-faceted growth opportunity with a diversified business and a de-risked clinical pipeline. We believe that the company’s ability to commercialize its 100% pure premium CBD products provides attractive immediate near-term revenue opportunities which significantly reduce downside scenarios for the overall business.
Cardiol is a company with world-leading strategic partners and is led by an impressive management team with a proven track record of success. During the last few weeks, Cardiol’s shares have recovered well and their move higher has taken place on increased volume and momentum (as measured by RSI). When compared to its peers, Cardiol has an attractive valuation and represents an opportunity with significant catalysts for growth. If you like to learn more, please email firstname.lastname@example.org
Pursuant to an agreement between StoneBridge Partners LLC and Empower Clinics we have been hired for a period of 180 days beginning May 1, 2019 and ending November 1, 2019 to publicly disseminate information about (CBDT) including on the Website and other media including Facebook and Twitter. We are being paid $6,000 per month (CBDT) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero (0) shares of (CBDT), which we purchased in the open market. We plan to sell the “ZERO” shares of (CBDT) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (CBDT) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.